Remdesivir for treatment of COVID-19 patients
Remdesivir, is approved in India for the treatment of suspected or laboratory confirmed incidences of COVID-19 in adults and children hospitalized with severe presentations of the disease. The COVID-19 disease is relatively new and as this drug has seen significant usage in hospitalized patients, there is a need for clinicians to share their experiences on the topic. Indian Medical...
Benefit of early intervention & role of Favipiravir in managing mild to moderate COVID-19 disease
As the incidence of COVID-19 cases continue to rise, we will need multiple approaches to effectively deal with this pandemic. Clinicians are evaluating Favipiravir for use in mild-to-moderate COVID-19 disease, which if administered early, may shorten time to recovery and keep the infection from progressing into severe disease. We welcome you to watch a recorded experience sharing...
Remdesivir for the Treatment of Severe COVID-19
Welcome to an exciting international exchange of experiences on "Remdesivir for the Treatment of Severe COVID-19"; the live webinar was held on 28th August 2020. In India, Remdesivir has been approved for emergency use in patients hospitalized with severe COVID-19 and has shown promising results. There is a need to more critically understand the utility of this drug,...
The race for COVID-19 treatment, Clinical trial outcomes & expert perspectives
The challenges of conducting trials against the backdrop of the COVID-19 pandemic will continue as we collectively journey into the “new normal”. Welcome to the recorded webinar on "The race for COVID-19 treatment; Clinical trial outcomes & expert perspectives". What will be covered: Situation of COVID-19 and health care workers in the state of Uttar Pradesh...
Use of Favipiravir in treatment of COVID-19 | Indian Phase 3 Clinical Trial Outcomes
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was declared a global pandemic in March 2020 by the WHO. During the time since it emerged into a global crisis, there have been several recommendations to prevent spread of infection and to manage COVID-19 infected patients through supportive care, plasma...
Sagar Panchal
Indian Medical Association-MS (IMA - MS)
Therapeutic
DR. SAGAR S. PANCHAL M.B.B.S, M.D (Pharmacology) SYNOPSIS Pharmaceutical physician by profession with strong academic & clinical background. Currently working as Medical advisor in Respiratory division of Glenmark Pharmaceuticals. Organized, efficient, reliable professional with proven... View Detail
Dr. Swami Digambar Pawar
Indian Medical Association-MS (IMA - MS)
Therapeutic
DR. SWAMI DIGAMBAR PAWAR EDUCATIONAL QUALIFICATION: MD Chest- Grant Medical College, Mumbai MBBS- G. S. Medical College, Mumbai MEMBERSHIPS: Life Member of Critical Care Foundation & College of Critical Care Medicine, India. Member American... View Detail
Dr. Swapnil Gautam
Indian Medical Association-MS (IMA - MS)
Therapeutic
DR. SWAPNIL GAUTAM MBBS, MD, DNB, MNAMS, PGDMLS, MRCP(London),MRCP(Edinburgh),MRCPS(Glasgow) PGDip Infectious Disease( University of New South Wales, Sydney) PGDip Infectious Disease( University of London ) ... View Detail
Dr. Pankaj Bandarkar
COVID-19 Resource Center
Coronavirus
Dr Pankaj Bandarkar Family Physician Hon. State secretary, IMA MS View Detail
COVID-19 Resource Center
The COVID-19 pandemic resulted in world-wide research efforts to better understand the disease causing virus and its treatment options. There is a growing wealth of information on COVID-19 related to its research, clinical presentation, and treatment outcomes. This resource center, supported by... View Detail
Viatris
Viatris is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine. Viatris is present in more than 165 countries and territories, and every member of their approximately 35,000-strong workforce is... View Detail